CONFIDENTIAL TREATMENT REQUESTED Portions of this exhibit indicated by “[***]” have been omitted, and such omitted portions have been filed separately with the Securities and Exchange Commission (SEC). Confidential treatment has been requested with...Confidential Treatment • October 1st, 2014 • Akorn Inc • Pharmaceutical preparations • New York
This Product Acquisition Agreement (this “Agreement”) is entered into as of September 30, 2014, by and among Sunovion Pharmaceuticals Inc., a Delaware corporation (“Seller”), Oak Pharmaceuticals, Inc., a Delaware corporation (“Purchaser”) and Akorn, Inc., a Louisiana corporation (“Parent”).
